Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biorxiv : the Preprint Server for Biology|April 27, 2026
Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Pathology International|June 23, 2026
Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate CancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Oncogene|June 18, 2026
The glycobiology of prostate cancer: an updateKirsty Hodgson, Margarita Orozco-Moreno, Ziqian Peng, et al.
Cancers|September 14, 2024
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer CellsEmily Archer Goode, Margarita Orozco-Moreno, Kirsty Hodgson, et al.
Scientific Reports|October 9, 2023
The role of GCNT1 mediated O-glycosylation in aggressive prostate cancerKirsty Hodgson, Margarita Orozco-Moreno, Emma Scott, et al.
Glycobiology|October 17, 2023
Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitorsMargarita Orozco-Moreno, Eline A Visser, Kirsty Hodgson, et al.
British Journal of Cancer|July 13, 2026
Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasisZiqian Peng, Kirsty Hodgson, Matthew Fisher, et al.
Cancer Medicine|May 19, 2025
FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation InhibitorsKayla Bastian, Margarita Orozco-Moreno, Huw Thomas, et al.
Ebiomedicine|May 21, 2024
Sialic acid blockade inhibits the metastatic spread of prostate cancer to boneKirsty Hodgson, Margarita Orozco-Moreno, Emily Archer Goode, et al.
The Journal of Pathology|August 7, 2023
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progressionEmma Scott, Emily Archer Goode, Rebecca Garnham, et al.
Pageof 2